{"database": "press", "table": "releases", "rows": [["https://hoyle.house.gov/media/press-releases/reps-hoyle-and-doggett-reintroduce-legislation-to-lower-prescription-drug-pricing", "REPS. HOYLE AND DOGGETT REINTRODUCE LEGISLATION TO LOWER PRESCRIPTION DRUG PRICING", "2026-08-13", "2026", "2026-08", "Democrat", "House", "OR", "Val T. Hoyle", "H001094", "hoyle.house.gov", "hoyle", "https://hoyle.house.gov/media/press-releases", "scraper", "Washington DC \u2013 Today, Representatives Val Hoyle (OR-04) and Lloyd Doggett (TX-37) reintroduced the Affordable Pricing for Taxpayer-Funded Prescription Drugs Act to lower the cost of prescription drugs for Americans. Building on the progress made in the Inflation Reduction Act, this bill would ensure Americans can finally afford lifesaving medicines by requiring affordable pricing agreements for any drug developed using federal funds.\n\n\u201cAmericans are struggling to afford essentials like gas, groceries and prescription drugs. In fact, drug prices in this country are 2.78 times higher than other developed countries,\u201d said Rep. Hoyle. \u201cIt\u2019s unacceptable that American taxpayers have to pay the price for Big Pharma\u2019s greed. The Affordable Pricing for Taxpayer-Funded Prescription Drugs Act will help working families by establishing affordable pricing agreements and improve transparency from manufacturers.\u201d\n\n\u201cAs Trump\u2019s secret deals with Big Pharma do nothing to lower drug prices for most consumers, this legislation delivers meaningful protections to ensure all Americans are charged fair and reasonable prices when taxpayers contribute research and development funding. Families struggling to afford gas, groceries, and most everything else under Trump tariff taxes shouldn\u2019t also be forced to ration or skip necessary medications because of his failure to restrain Big Pharma\u2019s monopoly power,\u201d said Rep. Doggett.\n\nEndorsements\n\nPublic Citizen\u2019s Access to Medicines Program \u2013 Peter Maybarduk, Director\n\n\u201cThe U.S. Government is the largest supporter of biomedical research and development in the world, yet U.S. patients and taxpayers are routinely charged 3-4 times the prices people in other large, wealthy countries pay for prescription drugs. Drug corporation profiteering off Americans for drugs we paid to invent is unjust and leads to preventable suffering and death. Public Citizen is grateful for Reps. Hoyle and Doggett introducing the Affordable Pricing for Taxpayer-Funded Prescription Drugs Act, which would expand access to affordable medicines and bring fairness through requiring federal agencies to include reasonable pricing requirements in licenses, contracts, and other agreements through which Americans support biomedical R&D.\u201d\n\nKnowledge Ecology International \u2013 James Love, Director\n\n\u201cThis is a very thoughtful and reasonable proposal. The requirement that US residents would not have to pay more than other high-income countries, when their tax dollars supported the research to develop a product, should not be controversial. The other provisions in the bill provide balance and nuance. The waiver provision provides even more flexibility, and is appropriately tied to transparency and public comment obligation, when used.\u201d\n\nBackground\n\nIn August 2022, Congressional Democrats passed the Inflation Reduction Act, giving Medicare the power to negotiate prices for the most expensive prescription drugs. While the Department of Health & Human Services has used this authority to save Americans billions, Big Pharma continues to raise prices and pad its bottom line. The Affordable Pricing for Taxpayer-Funded Prescription Drugs Act builds on this reform by ensuring the federal government can use its leverage earlier in the drug development process. The bill:", 1, "2026-08-14T06:13:05Z", "2026-08-14T06:14:08Z"]], "columns": ["url", "title", "date", "year", "month", "party", "chamber", "state", "member_name", "bioguide_id", "domain", "scraper", "source", "date_source", "text", "has_text", "collected_at", "updated_at"], "primary_keys": ["url"], "primary_key_values": ["https://hoyle.house.gov/media/press-releases/reps-hoyle-and-doggett-reintroduce-legislation-to-lower-prescription-drug-pricing"], "units": {}, "query_ms": 1.393742859363556, "source": "dwillis/congress-press", "source_url": "https://github.com/dwillis/congress-press", "license": "MIT", "license_url": "https://github.com/dwillis/congress-press/blob/main/LICENSE"}